Medical Condition News

RSS

Quark Pharmaceuticals commences dosing in clinical study of QPI-1007 for NAION

Quark Pharmaceuticals, Inc., a world leader in the discovery and development of RNAi-based therapeutics, announced today the dosing of the first patient in a Phase I study of the investigational neuroprotective agent, QPI-1007.

2 Mar 2010

WHO Director-General calls for greater efforts to reduce tobacco use

In a speech on Friday marking the fifth anniversary of an international tobacco control treaty, WHO Director-General Margaret Chan called for government officials worldwide to increase efforts to protect their population from the harmful effects of tobacco, Reuters reports. "Tobacco kills more than 5 million people a year from cardiovascular disease, cancers, diabetes and other chronic illnesses, including about 600,000 from second-hand smoke, according to the United Nations agency," the news service writes.

1 Mar 2010

Acorda Therapeutics' AMPYRA now available in the U.S. and Puerto Rico

Acorda Therapeutics, Inc. today announced that AMPYRA™ (dalfampridine) Extended Release Tablets, 10 mg is now available by prescription in the United States and Puerto Rico. AMPYRA was approved on January 22, 2010 by the U.S. Food and Drug Administration (FDA) as a treatment to improve walking in patients with multiple sclerosis (MS). This was demonstrated by an increase in walking speed. AMPYRA is indicated for use in all types of MS, and can be used either alone or with existing therapies, including disease-modifying agents.

1 Mar 2010

Scopolamine drug: A rapid-acting antidepressant for depression symptoms

Conventional antidepressant treatments generally require three to four weeks to become effective, thus the discovery of treatments with a more rapid onset is a major goal of biological psychiatry. The first drug found to produce rapid improvement in mood was the NMDA glutamate receptor antagonist, ketamine.

1 Mar 2010

ChemGenex Pharmaceuticals' OMAPRO review: FDA reschedules ODAC meeting to 22 March, 2010

ChemGenex Pharmaceuticals Limited announced today that the U.S. Food and Drug Administration (FDA) has rescheduled the previously postponed Oncologic Drugs Advisory Committee (ODAC) meeting to 22 March 2010.

1 Mar 2010

COMP issues positive opinion for Æterna Zentaris' perifosine orphan medicinal product designation

Æterna Zentaris Inc., a late-stage drug development company specialized in oncology and endocrinology, today announced that it has received a positive opinion for orphan medicinal product designation for its compound perifosine from the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency, for the treatment of multiple myeloma.

1 Mar 2010

Biodel seeks FDA marketing approval for VIAject

Biodel Inc. announced today that the U.S. Food and Drug Administration has accepted for review the company’s new drug application (NDA) seeking approval to market VIAject® for the treatment of diabetes. VIAject® is Biodel's proprietary formulation of recombinant human insulin that is designed to be absorbed into the blood faster than currently marketed rapid-acting insulin analogs.

1 Mar 2010

FDA accepts for filing VIVUS' Qnexa NDA

VIVUS, Inc. today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the company's new drug application (NDA) for its investigational drug, Qnexa®, for the treatment of obesity. The target date for the FDA to complete its review of the Qnexa NDA is October 28, 2010.

1 Mar 2010

Uroplasty's Urgent PC Neuromodulation System SUmiT Trial demonstrates effectiveness of PTNS

Uroplasty, Inc., a medical device company that develops, manufactures and markets innovative proprietary products to treat voiding dysfunctions, today highlighted results of the SUmiT Trial of its Urgent® PC Neuromodulation System that will be published in the April 2010 print edition of THE JOURNAL OF UROLOGY® and is now available on line.

1 Mar 2010

Peer-reviewed articles elucidate role of clusterin in promoting tumor resistance to cancer treatment

OncoGenex Pharmaceuticals, Inc., announced today that two peer-reviewed articles have been published that further elucidate the biological function of clusterin, its role in promoting tumor resistance to cancer treatment, and the role of an inhibitor of clusterin such as custirsen (OGX-011) that is designed to knock down treatment resistance in the cells and enhance the effectiveness of cancer therapies.

1 Mar 2010

Study compares advertising tactics between indoor tanning and tobacco industries to market unhealthy products

While the proven negative health consequences of smoking and tanning are undeniable, tobacco and indoor tanning advertisers would like consumers to think otherwise. In fact, a new study comparing the tactics used in advertising tobacco and indoor tanning products found several similarities in how these two industries market unhealthy products.

1 Mar 2010

SUVmax in head and neck squamous cell carcinoma patients predict overall survival

The maximal standardized uptake value (called SUVmax) measured from FDG PET readings taken from the primary tumor in head and neck squamous cell carcinoma patients before treatment is a strong predictor of disease-specific survival, overall survival and disease-free survival, while pretreatment SUVmax for lymphodenopathy is strongly associated with distant metastasis, according to a study presented at the Multidisciplinary Head and Neck Cancer Symposium, sponsored by AHNS, ASCO, ASTRO and SNM.

1 Mar 2010

Synexus recruits 87% of agreed number of patients in major osteoporosis study within deadline

Following the recent announcement from Manchester-based Synexus that they had randomised 2,700 patients in just ten months for an osteoporosis study, the company has once again demonstrated that it is possible to recruit the agreed number of patients within the study deadline by recruiting 87% of patients to another study for the same therapeutic area.

From AES - Accelerated Enrollment Solutions 1 Mar 2010

Determining personal risk for genetic disorders essential

Genetic diseases affect an estimated 12 million Americans, yet according to a survey of 1,000 people conducted by the Genetic Disease Foundation (GDF), while two-thirds of those surveyed were willing to and saw the benefits of undergoing genetic testing, close to 80 percent had never talked to their physician about genetic screening – an inconsistency that can have serious implications on a person's overall health and the health of their immediate family members.

1 Mar 2010

arGEN-X SIMPLE Antibody platform delivers multiple, diverse, ultra-potent functional antibodies

SIMPLE Antibody(TM) Platform Delivers Unprecedented Choice of Ultra-Potent Functional Antibody Leads Against Challenging Soluble and Cell Surface Targets. - ARGX-109, a Fully Human mAb Targeting Autoimmune, Inflammation and Oncology Indications, Enters Preclinical Development in Less Than 12 Months From Start of Discovery.

1 Mar 2010

Study on new drug targets for prevention of tissue inflammation after stroke

Researchers at Albany Medical College are releasing results of a study this week that they say will help refocus the search for new drug targets aimed at preventing or reversing the devastating tissue inflammation that results after heart attack and stroke.

1 Mar 2010

Government has yet to confirm funding for ADI

With the sunset date for the Aboriginal Diabetes Initiative (ADI) rapidly approaching, the government has yet to confirm whether or not funding will continue after March 31st.

1 Mar 2010

Two stroke-prevention procedures are equally beneficial for men and women, but effectiveness vary by age

Two stroke-prevention procedures are safe and equally beneficial for men and women at risk for stroke, but the effectiveness does vary by age, say researchers at the University of Alabama at Birmingham in collaboration with other North American stroke investigators.

1 Mar 2010

JACI supplement supports the importance of small airways in asthma management

Increasing evidence supports the importance of small airways in the diagnosis and treatment of asthma; however, focused areas of discussion and critical review of this topic have been lacking. To foster a better understanding of the role of small airways in asthma management, Teva Respiratory, a subsidiary of Teva Pharmaceutical Industries Ltd., will be providing reprints of a special supplement entitled "Small Airway Involvement: A Key to Asthma" from the December issue of the Journal of Allergy and Clinical Immunology at their exhibit (Booth #724) at the American Academy of Allergy, Asthma & Immunology Annual Meeting being held Feb. 26-March 2, 2010 in New Orleans, La.

1 Mar 2010

Using genetic engineering techniques in pigs, scientists create new model of diabetes

The incidence of diabetes is rising worldwide. Using genetic engineering techniques in pigs, scientists at Ludwig-Maximilians-Universität in Munich have created a new model of this metabolic disorder, which recapitulates many features of the disease, and promises to contribute significantly to improvements in diagnosis and therapy.

1 Mar 2010

Medical Condition News

Quark Pharmaceuticals commences dosing in clinical study of QPI-1007 for NAION

WHO Director-General calls for greater efforts to reduce tobacco use

Acorda Therapeutics' AMPYRA now available in the U.S. and Puerto Rico

Scopolamine drug: A rapid-acting antidepressant for depression symptoms

ChemGenex Pharmaceuticals' OMAPRO review: FDA reschedules ODAC meeting to 22 March, 2010

COMP issues positive opinion for Æterna Zentaris' perifosine orphan medicinal product designation

Biodel seeks FDA marketing approval for VIAject

FDA accepts for filing VIVUS' Qnexa NDA

Uroplasty's Urgent PC Neuromodulation System SUmiT Trial demonstrates effectiveness of PTNS

Peer-reviewed articles elucidate role of clusterin in promoting tumor resistance to cancer treatment

Study compares advertising tactics between indoor tanning and tobacco industries to market unhealthy products

SUVmax in head and neck squamous cell carcinoma patients predict overall survival

Synexus recruits 87% of agreed number of patients in major osteoporosis study within deadline

Determining personal risk for genetic disorders essential

arGEN-X SIMPLE Antibody platform delivers multiple, diverse, ultra-potent functional antibodies

Study on new drug targets for prevention of tissue inflammation after stroke

Government has yet to confirm funding for ADI

Two stroke-prevention procedures are equally beneficial for men and women, but effectiveness vary by age

JACI supplement supports the importance of small airways in asthma management

Using genetic engineering techniques in pigs, scientists create new model of diabetes

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Latest News